Adjuvanted H5N1 pandemic influenza vaccine

BIOLOGICAL3 trials

Sponsors

Novartis Vaccines

Conditions

Pandemic H5N1 Influenza

Phase 2

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

CompletedNCT01766921

Novartis VaccinesPandemic H5N1 Influenza

Start: 2013-01-31End: 2014-07-31Updated: 2019-01-30

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

CompletedNCT01776541

Novartis VaccinesPandemic H5N1 Influenza

Start: 2013-01-31End: 2014-05-31Updated: 2015-02-03

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

CompletedNCT01776554

Novartis VaccinesPandemic H5N1 Influenza

Start: 2013-01-31End: 2014-06-30Updated: 2019-01-16

Related Papers

Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults

Vaccines2021-12-117 citations

Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects

Vaccine2021-10-2510 citations

Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects

The Pediatric Infectious Disease Journal2019-05-0610 citations

Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly.

2019-03-0111 citations